Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
This trial is active, not recruiting.
|Condition||gram-negative bacterial infections|
|Sponsor||University of Pittsburgh|
|Start date||September 2005|
|End date||December 2016|
|Trial size||1000 participants|
|Trial identifier||NCT00177814, IRB # 0508074|
The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.
dead or alive
time frame: end of study
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin
|Official title||Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit|
|Principal investigator||David Paterson, MD|
|Description||The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history.|
Call for more information